

MDC Pharmacokinetics (PK) II Practice Exam (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 - 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. Levox is a brand name for Levofloxacin produced by which supplier?**
 - A. UAP**
 - B. GSK**
 - C. Pfizer**
 - D. Westmont**

- 2. In pediatric pharmacokinetics, clearance is commonly adjusted using allometric scaling with body weight. What does allometric scaling use?**
 - A. A power-law relationship between clearance and body weight**
 - B. An linear relationship with age**
 - C. A fixed multiplier regardless of weight**
 - D. Only BMI**

- 3. Would a loading dose accelerate the time to reach therapeutic concentration?**
 - A. Accelerates time to reach therapeutic concentration**
 - B. Slows time to reach therapeutic concentration**
 - C. No change in time to reach concentration**
 - D. Increases duration of subtherapeutic**

- 4. Amoxicillin belongs to which antibiotic class?**
 - A. Cephalosporins**
 - B. Penicillins**
 - C. Macrolides**
 - D. Tetracyclines**

- 5. What sampling strategies are used in population PK modeling?**
 - A. Rich sampling for individuals or sparse sampling across population; NLME uses both.**
 - B. Only rich sampling for individuals.**
 - C. Only sparse sampling across population.**
 - D. Random sampling.**

6. For an oral drug with k_a and k_e , under what condition will t_{max} occur after oral administration?
- A. $k_a < k_e$
 - B. $k_a = k_e$
 - C. $k_a > k_e$ and $dC/dt = 0$; $t_{max} \approx (\ln(k_a) - \ln(k_e)) / (k_a - k_e)$
 - D. t_{max} occurs at $t = 0$
7. Rifampicin is supplied under which brand name in the list?
- A. Rimactane
 - B. Celestone
 - C. Decilone
 - D. Medrol
8. Which antibiotic is a quinolone?
- A. Minocycline
 - B. Amoxicillin
 - C. Ofloxacin
 - D. Rifampicin
9. In a two-compartment pharmacokinetic model, what are the names of the distribution and elimination phases?
- A. Alpha phase and Beta phase
 - B. Gamma phase and Delta phase
 - C. Delta phase and Gamma phase
 - D. Initial and Terminal phase
10. What is the effect of enzyme induction on Cl_{int} , clearance, and exposure?
- A. Induction increases Cl_{int} , increasing Cl , reducing AUC and C_{ss} .
 - B. Induction decreases Cl_{int} , decreasing Cl , increasing AUC.
 - C. Induction has no effect on clearance or exposure.
 - D. Induction decreases C_{ss} but increases AUC.

Answers

SAMPLE

1. D
2. A
3. A
4. B
5. A
6. C
7. A
8. C
9. A
10. A

SAMPLE

Explanations

SAMPLE

1. Levox is a brand name for Levofloxacin produced by which supplier?

- A. UAP
- B. GSK
- C. Pfizer
- D. Westmont**

Brand names for a drug are chosen and marketed by specific manufacturers, and the same active ingredient can carry different brand names in different regions or from different suppliers. Levox is a brand name used for levofloxacin by a particular supplier, Westmont. That's why the supplier associated with Levox is Westmont. In other markets or catalogs, levofloxacin may appear under other brands from other companies, so brand-to-supplier mappings aren't universal. The other companies listed produce their own brands, but Levox is not their brand in the typical reference for this question.

2. In pediatric pharmacokinetics, clearance is commonly adjusted using allometric scaling with body weight. What does allometric scaling use?

- A. A power-law relationship between clearance and body weight**
- B. An linear relationship with age
- C. A fixed multiplier regardless of weight
- D. Only BMI

Allometric scaling uses a power-law relationship between clearance and body weight. In practice, clearance is modeled as $CL = CL_{ref} \times (WT / WT_{ref})^b$, with an exponent b typically around 0.75 for clearance. This non-linear scaling reflects how physiological processes like organ size and blood flow don't increase in direct proportion to weight. For example, doubling body weight increases clearance by about $2^{0.75} \approx 1.68$, not by a factor of 2. BMI or age alone don't capture this size-dependent change as effectively as the weight-based power law does. In pediatrics, this approach helps predict how clearance changes across a wide range of weights, guiding appropriate dosing.

3. Would a loading dose accelerate the time to reach therapeutic concentration?

- A. Accelerates time to reach therapeutic concentration**
- B. Slows time to reach therapeutic concentration
- C. No change in time to reach concentration
- D. Increases duration of subtherapeutic

A loading dose speeds up reaching the therapeutic level by instantly elevating the drug's plasma concentration to the target level, rather than waiting for multiple maintenance doses to accumulate. In linear pharmacokinetics, the loading dose is chosen so that the initial amount in the body places the concentration at the desired therapeutic value (roughly $LD \approx C_{target} \times Vd$). After that, maintenance dosing keeps concentrations within the therapeutic range as the drug is eliminated. Without a loading dose, it takes several half-lives for the drug to build up to therapeutic levels, delaying onset. Of course, a high initial dose can raise peak levels and risk toxicity, so monitoring is important.

4. Amoxicillin belongs to which antibiotic class?

- A. Cephalosporins
- B. Penicillins**
- C. Macrolides
- D. Tetracyclines

Amoxicillin is part of the penicillin family, a type of beta-lactam antibiotic. It works by inhibiting bacterial cell wall synthesis through the penicillin-binding proteins, which prevents cross-linking of the peptidoglycan layer and leads to bacterial death. It belongs to penicillins rather than cephalosporins, macrolides, or tetracyclines, which have different structures and mechanisms: cephalosporins are another beta-lactam class with a similar mechanism but a separate family, macrolides inhibit protein synthesis at the 50S ribosome, and tetracyclines inhibit the 30S ribosome. Amoxicillin is specifically an aminopenicillin with good oral bioavailability, distinguishing it within the penicillin group.

5. What sampling strategies are used in population PK modeling?

- A. Rich sampling for individuals or sparse sampling across population; NLME uses both.**
- B. Only rich sampling for individuals.
- C. Only sparse sampling across population.
- D. Random sampling.

Population PK modeling aims to describe what the drug does in the body for the typical individual and how people differ. To do this, sampling designs fall into two main approaches: richly detailed concentration-time data from a few subjects, and sparse samples from many subjects. Nonlinear mixed-effects modeling can handle either design and can even combine them in one analysis. Rich sampling gives precise, complete profiles that help pin down the structural model and parameter values for individuals. Sparse sampling across a population provides broad coverage, enabling robust estimation of the typical population parameters and the variability between subjects, by borrowing strength from the entire dataset. In practice, many studies use a mixed design—some subjects with dense sampling and others with sparse sampling—to maximize information while keeping study size and logistics reasonable. Random sampling alone doesn't define the standard population PK approach; the key idea is using either rich data or sparse data across many subjects within a nonlinear mixed-effects framework.

6. For an oral drug with k_a and k_e , under what condition will t_{max} occur after oral administration?

A. $k_a < k_e$

B. $k_a = k_e$

C. $k_a > k_e$ and $dC/dt = 0$; $t_{max} \approx (\ln(k_a) - \ln(k_e)) / (k_a - k_e)$

D. t_{max} occurs at $t = 0$

When a drug is absorbed and eliminated by first-order processes, the peak plasma concentration occurs when the rate of absorption equals the rate of elimination. Mathematically, that happens when $dC/dt = 0$, which for this system leads to a finite t_{max} only if the absorption rate constant is greater than the elimination rate constant ($k_a > k_e$). In that case, the time to peak is approximately $t_{max} = [\ln(k_a) - \ln(k_e)] / (k_a - k_e)$. If $k_a \leq k_e$, there is no finite peak time: with $k_a = k_e$ the peak would occur at infinity, and with $k_a < k_e$ the concentration rises without a true maximum. The t_{max} at $t = 0$ would imply an immediate peak, which doesn't happen because absorption takes time.

7. Rifampicin is supplied under which brand name in the list?

A. Rimactane

B. Celestone

C. Decilone

D. Medrol

Rifampicin (rifampin) is an antibiotic used mainly in TB therapy, and one of its well-known trade names is Rimactane. Among the options listed, Rimactane is the brand name associated with rifampicin, while the other names are corticosteroids (for example, Celestone and Medrol are brands for steroids), not antibiotics. Brand names can vary by country, but Rimactane is the correct match for rifampicin here.

8. Which antibiotic is a quinolone?

A. Minocycline

B. Amoxicillin

C. Ofloxacin

D. Rifampicin

Quinolones kill bacteria by blocking enzymes essential for DNA replication, mainly DNA gyrase and topoisomerase IV. Ofloxacin is a fluoroquinolone, a member of this class, so it shares that mechanism and is considered a quinolone. The other drugs are from different classes: minocycline is a tetracycline that inhibits the 30S ribosome; amoxicillin is a beta-lactam that disrupts cell wall synthesis; rifampicin inhibits bacterial RNA polymerase. Thus, Ofloxacin is the quinolone among the options.

9. In a two-compartment pharmacokinetic model, what are the names of the distribution and elimination phases?

- A. Alpha phase and Beta phase**
- B. Gamma phase and Delta phase**
- C. Delta phase and Gamma phase**
- D. Initial and Terminal phase**

In a two-compartment pharmacokinetic model, the early, rapid change in drug concentration reflects distribution between the central and peripheral compartments and is called the alpha phase. The later, slower decline represents the elimination of drug from the body and is called the beta phase. Mathematically, the concentration over time is described by two exponential terms, with alpha governing the distribution and beta governing elimination. In this two-compartment scenario there isn't a separate gamma or delta phase—that terminology appears in more complex multi-compartment models.

10. What is the effect of enzyme induction on Cl_{int} , clearance, and exposure?

- A. Induction increases Cl_{int} , increasing Cl, reducing AUC and C_{ss} .**
- B. Induction decreases Cl_{int} , decreasing Cl, increasing AUC.**
- C. Induction has no effect on clearance or exposure.**
- D. Induction decreases C_{ss} but increases AUC.**

When enzymes are induced, the liver increases its metabolic capacity, raising intrinsic clearance (Cl_{int}). With Cl_{int} higher, hepatic clearance (Cl) goes up because more drug is removed per unit time, especially when Cl_{int} is not already limited by blood flow. For a given dose delivered IV, exposure is inversely related to clearance: $AUC = \text{Dose}/Cl$, so as clearance rises, AUC falls. Likewise, at a constant dosing rate (as in a steady IV infusion), steady-state concentration $C_{ss} = \text{Rate}_{in} / Cl$; higher clearance leads to a lower C_{ss} . Therefore, enzyme induction raises Cl_{int} , increases clearance, and reduces both exposure (AUC) and steady-state concentration (C_{ss}).

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://mdcpk2.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE